FCA
LGND icon

FinTrust Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

FinTrust Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-285
Closed -$18K – 1092
2019
Q3 		$18K Buy
285
+45
+19% +$2.83K 0.01% 672
2019
Q2 		$17K Sell
240
-300
-56% -$22.1K 0.01% 639
2019
Q1 		$43K Buy
540
+211
+64% +$16K 0.02% 419
2018
Q4 		$28K Buy
+329
New +$35.1K 0.01% 508

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

FinTrust Capital Advisors's LGND Position: Q4 2019 in Review

FinTrust Capital Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 285 shares — an estimated $18K sold.

FinTrust Capital Advisors first reported a position in LGND in Q4 2018 and held it in 4 quarters. The position peaked at $43K in Q1 2019. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

  • FinTrust Capital Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • FinTrust Capital Advisors sold 285 Ligand Pharmaceuticals shares in Q4 2019, an estimated $18K.
  • FinTrust Capital Advisors first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • FinTrust Capital Advisors's Ligand Pharmaceuticals position peaked at $43K in Q1 2019.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on FinTrust Capital Advisors's 13F filing for Q4 2019, filed 23 Jan 2020.